Albutrepenonacog alfa
Established medicineAlso known as IDELVION, Coagulation Factor IX (Recombinant), Albumin Fusion Protein, Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP).
Recent clinical, regulatory, research and industry developments relating to this drug.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).
Evidence ↗Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Regulatory event sources are credited in the Regulatory Timeline above.